Modulation of anti-Candida activity of human alveolar macrophages by interferon-gamma or interleukin-1-alpha.
The fungicidal and bactericidal activities of human alveolar macrophages (AM) and peripheral blood monocytes (PBM) from 18 healthy volunteers were evaluated. The results showed that AM were able to phagocytize and kill Candida albicans, Pseudomonas aeruginosa, and Staphylococcus aureus. However, killing of the bacteria was already complete in 2 h, whereas killing of Candida required 4 to 6 h despite an early phagocytosis of yeast cells. The fungicidal activity of freshly collected AM and PBM was also tested after effector cell exposure to interferon-gamma (IFN-gamma), interleukin-1-alpha (IL-1 alpha), endotoxin lipopolysaccharide (LPS), or interleukin 2 (IL-2). It was found that treatment with IFN-gamma, IL-1 alpha, or LPS significantly augmented macrophage and PBM candidacidal activity, whereas the addition of IL-2 was ineffective. We also evaluated killing of C. albicans by AM cultured in vitro for different times. While phagocytosis was apparently unaffected, the candidacidal activity progressively decreased over the in vitro culture period, an effect that was largely reversed by cell exposure to IFN-gamma, IL-1 alpha, or LPS. In an experimental model in which mice infected with an agerminative C. albicans strain (PCA-2) resisted lethal microbial challenge, freshly harvested AM showed increased cytotoxic activity to Aspergillus fumigatus in vitro as well as enhanced IL-1 production. In conclusion, present data confirm the crucial role of AM in the surveillance of bacterial and fungal infections and indicate that treatment of these cells with IFN-gamma or IL-1 alpha is able to enhance their antimicrobial capability.
Vecchiarelli
A
A
Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.
Todisco
T
T
Puliti
M
M
Dottorini
M
M
Bistoni
F
F
D000328:Adult; D000818:Animals; D001232:Aspergillus fumigatus; D002176:Candida albicans; D002478:Cells, Cultured; D003114:Colony-Forming Units Assay; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D007375:Interleukin-1 / Q000494:pharmacology*; D007376:Interleukin-2 / Q000494:pharmacology; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology; D008168:Lung; D008213:Lymphocyte Activation; D008264:Macrophages / Q000187:drug effects / Q000502:physiology*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000502:physiology*; D010587:Phagocytosis / Q000187:drug effects*; D011550:Pseudomonas aeruginosa; D012016:Reference Values; D013211:Staphylococcus aureus
D007375:Interleukin-1; D007376:Interleukin-2; D008070:Lipopolysaccharides; D007371:Interferon-gamma